サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1709466

肺線維症バイオマーカーの世界市場：バイオマーカーの種類別・用途別・エンドユーザー別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2025年～2032年)

Pulmonary Fibrosis Biomarkers Market, By Type of Biomarkers, By Application, By End-user, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日
ページ情報
英文 301 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
肺線維症バイオマーカーの世界市場：バイオマーカーの種類別・用途別・エンドユーザー別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2025年～2032年)
出版日: 2025年03月04日
発行: AnalystView Market Insights
ページ情報: 英文 301 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

肺線維症バイオマーカー市場規模は2024年に42億9,043万米ドルとなり、2025年から2032年にかけてCAGR 4.50%で拡大

肺線維症バイオマーカーの市場力学

肺線維症の罹患率増加が診断におけるバイオマーカー需要を促進

肺線維症（PF）の罹患率の増加は、バイオマーカー市場成長の主要な促進要因です。インドのような国では、特発性肺線維症（IPF）の有病率が上昇しており、人口10万人あたり14～43人と推定されています。このような症例数の増加は、早期かつ正確な診断の緊急性を浮き彫りにしています。ある調査によると、IPFは国内の間質性肺疾患（ILD）全体の約17％を占めており、この疾患を早期に発見して効果的に管理することの重要性が強調されています。さらに、プネーなどの地域では、IPF症例が年間5～7％増加しており、高度な診断ツールの需要がさらに高まっています。肺線維症の症例が世界的に増加し続ける中、診断、病勢進行のモニタリング、治療効果の評価を可能にする信頼性の高いバイオマーカーの必要性がこれまで以上に高まっており、この市場における技術革新への需要が高まっています。

肺線維症バイオマーカー市場：主な考察

弊社リサーチアナリストの分析によると、世界市場は予測期間（2025-2032年）に約4.50%のCAGRで毎年成長すると予測されています。

バイオマーカーの種類別によると、診断バイオマーカーが2024年に最大の市場シェアを示すと予測されています。

用途別では、診断が2024年の主要用途です。

エンドユーザー別では、診断検査室が2024年の主要エンドユーザーです。

地域別では、北米が2024年の主要収益源です。

肺線維症バイオマーカー市場：セグメンテーション分析

肺線維症バイオマーカーの世界市場は、バイオマーカーの種類、用途、エンドユーザー、地域に基づいてセグメント化されます。

バイオマーカーの種類によって市場は3つに分類されます：診断バイオマーカー、予後バイオマーカー、予測バイオマーカーです。診断バイオマーカー分野は、肺線維症バイオマーカー市場で最も顕著かつ重要です。肺線維症（PF）の早期かつ正確な診断は、患者の予後を改善するために極めて重要であり、診断バイオマーカーはこのプロセスにおいて重要な役割を果たしています。これらのバイオマーカーは、介入によって疾患の進行を遅らせることができる初期段階で肺線維症の存在を特定するために不可欠です。特発性肺線維症（IPF）のような疾患は、他の肺疾患との類似性から診断が困難であるため、診断バイオマーカーはPFと他の疾患との鑑別に役立ち、より迅速で正確な診断につながります。KL-6、SP-D、CCL18などのバイオマーカーは、IPFやその他の肺線維症の診断に役立つため、臨床の場でますます使用されるようになってきています。米国のような地域では、PFに対する認識が高まっており、発症率も高いことから、信頼性の高い診断ツールの必要性がさらに高まっています。この需要により、より効率的な新規バイオマーカーの研究開発が推進され、診断用バイオマーカー分野が市場の優位性を維持しています。

市場は用途別に3つのカテゴリーに分類されます：診断、治療モニタリング、医薬品開発です。肺線維症バイオマーカー市場で最も重要なのは診断分野です。肺線維症（PF）の早期かつ正確な診断は、患者の予後を改善し、タイムリーな治療を可能にするために極めて重要です。肺線維症、特に特発性肺線維症（IPF）は、他の肺疾患と症状が共通するため、誤診されることが多く、診断バイオマーカーは類似疾患との鑑別に不可欠です。KL-6、SP-D、CCL18などのバイオマーカーは、疾患の進行を遅らせるための介入が最も効果的である早期段階でPFを検出する能力があるため、臨床で一般的に使用されています。PFの有病率の上昇に伴い、正確な診断ツールに対する需要が高まっており、早期発見のための新たなバイオマーカーの開発に注目が集まっています。さらに、研究機関や医療提供者が早期診断を重視する中、診断アプリケーションは肺線維症バイオマーカー市場の成長と革新の中心であり続けています。

肺線維症バイオマーカー市場：地域別分析

北米は、先進的な医療インフラ、肺疾患の高い有病率、継続的な研究イニシアチブにより、肺線維症バイオマーカー市場の主要地域となっています。特に米国は、トップクラスの研究機関や製薬会社の存在、臨床試験の増加に支えられ、市場で大きなシェアを占めています。米国では約20万人が特発性肺線維症（IPF）と診断されており、早期発見・早期管理を支援する診断バイオマーカーに対する需要は高いです。さらに、米国国立衛生研究所（NIH）のような政府プログラムは、バイオマーカーの同定と検証のための研究に資金を提供しており、技術革新を後押ししています。この地域の強力な医療償還制度も、新たなバイオマーカーが臨床診療に採用されることを確実にしています。さらに、病気に対する意識の高まりと個別化医療の進歩が、市場の成長をさらに後押ししています。

米国は、先進的な医療システムと医学研究への多額の投資により、肺線維症バイオマーカー市場で支配的な役割を果たしています。特発性肺線維症（IPF）と診断された患者数は20万人を超えており、早期発見、予後予測、治療モニタリングのための効果的なバイオマーカーの需要が急速に高まっています。

米国政府は、国立衛生研究所（NIH）などの機関を通じて、新しいバイオマーカーを発見するための研究に多額の資金を提供しています。その結果、IPFの診断ツールや治療法の開発が加速しています。また、バイオマーカー主導の解決策を進めるために研究機関と積極的に協力している強力な製薬業界も、この国の誇りです。

肺線維症バイオマーカー市場：競合情勢

肺線維症バイオマーカー市場の競合情勢は、大手製薬企業とバイオテクノロジー専門企業の存在によって特徴付けられます。ジェネンテック、F.ホフマン・ラ・ロシュ、ギリアド・サイエンシズなどの大手企業は、肺疾患における広範な研究能力と強固なポートフォリオにより、市場を独占しています。

これらの企業は、バイオマーカー探索の推進、臨床試験の実施、治療プロトコールへのバイオマーカーの統合に注力しています。同時に、Biodesix社やThermo Fisher Scientific社のような小規模のバイオテクノロジー企業も、肺線維症に合わせた革新的なバイオマーカープラットフォームや診断ツールで大きく前進しています。競合環境は、バイオマーカーの検証や商品化を加速させることを目的とした、製薬会社と研究機関の戦略的提携によっても促進されています。市場の進化に伴い、個別化医療のアプローチを採用する企業が増えており、競争がさらに激化しています。

目次

第1章 肺線維症バイオマーカー市場の概要

  • 調査範囲
  • 市場推定期間

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 肺線維症バイオマーカーの主な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 肺線維症バイオマーカー市場：産業分析

  • PEST分析
  • ポーターのファイブフォース分析
  • 市場成長の見通し：マッピング
  • 規制体制の分析

第5章 肺線維症バイオマーカー市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 肺線維症バイオマーカーの市場情勢

  • 肺線維症バイオマーカーの市場シェア分析 (2024年)
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 肺線維症バイオマーカー市場：バイオマーカーの種類別

  • 概要
    • セグメント別シェア分析：バイオマーカーの種類別
    • 診断バイオマーカー
    • 予後バイオマーカー
    • 予測バイオマーカー

第8章 肺線維症バイオマーカー市場：用途別

  • 概要
    • セグメント別シェア分析：用途別
    • 診断
    • 治療モニタリング
    • 医薬品開発

第9章 肺線維症バイオマーカー市場：エンドユーザー別

  • 概要
    • セグメント別シェア分析：エンドユーザー別
    • 病院・診療所
    • 診断検査室
    • 研究・学術機関

第10章 肺線維症バイオマーカー市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • オランダ
    • スウェーデン
    • ロシア
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋の主要メーカー
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • インドネシア
    • タイ
    • フィリピン
    • その他
  • ラテンアメリカ（LATAM）
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ（MEA）
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析：肺線維症バイオマーカー業界

  • 競合ダッシュボード
    • 競合ベンチマーク
    • 競合ポジショニング
  • 企業プロファイル
    • Biodesix, Inc.
    • Genentech, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Bristol-Myers Squibb Company
    • AbbVie Inc.
    • Thermo Fisher Scientific Inc.
    • Abbott Laboratories
    • PerkinElmer, Inc.
    • Eli Lilly and Company
    • Gilead Sciences, Inc.
    • Novartis International AG
    • Johnson &Johnson
    • Mylan NV
    • Sanofi SA
    • Amgen Inc.

第12章 AnalystViewの全方位的分析

目次
Product Code: ANV4936

REPORT HIGHLIGHT

Pulmonary Fibrosis Biomarkers Market size was valued at US$ 4,290.43 Million in 2024, expanding at a CAGR of 4.50% from 2025 to 2032.

Pulmonary fibrosis biomarkers are biological indicators that help in the diagnosis, monitoring, and prognosis of pulmonary fibrosis, a progressive lung disease characterized by scarring of lung tissue. These biomarkers can be proteins, genes, or other molecules present in blood, urine, or tissue samples. They assist in understanding the disease's progression and response to treatment. Biomarkers such as KL-6, SP-D, and CCL18 are often used to monitor disease activity and predict outcomes. Research into pulmonary fibrosis biomarkers is crucial for early detection, personalized treatments, and the development of new therapies. These biomarkers also help differentiate pulmonary fibrosis from other lung diseases with similar symptoms. As the disease can be difficult to diagnose, biomarkers provide valuable insights for clinicians to make more accurate decisions. With ongoing studies, these biomarkers are increasingly seen as essential tools for better patient management.

Pulmonary Fibrosis Biomarkers Market- Market Dynamics

Rising incidence of pulmonary fibrosis drives demand for biomarkers in diagnosis.

The increasing incidence of pulmonary fibrosis (PF) is a key driver for the growth of the biomarkers market. In countries like India, the prevalence of idiopathic pulmonary fibrosis (IPF) is rising, with estimates ranging between 14 to 43 per 100,000 people. This growing number of cases highlights the urgent need for early and accurate diagnosis. A study revealed that IPF accounts for approximately 17% of all interstitial lung diseases (ILDs) in the country, emphasizing the importance of detecting the condition early to manage it effectively. Furthermore, regions like Pune have seen a 5-7% annual increase in IPF cases, which further underscores the demand for advanced diagnostic tools. As pulmonary fibrosis cases continue to rise globally, the need for reliable biomarkers that can diagnose, monitor disease progression, and assess treatment efficacy is more critical than ever, driving the demand for innovation in this market.

Pulmonary Fibrosis Biomarkers Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.50% over the forecast period (2025-2032)

Based on Type of Biomarkers segmentation, Diagnostic Biomarkers was predicted to show maximum market share in the year 2024

Based on application segmentation, Diagnosis was the leading application in 2024

Based on End-user segmentation, Diagnosis laboratories was the leading End-user in 2024

On the basis of region, North America was the leading revenue generator in 2024

Pulmonary Fibrosis Biomarkers Market- Segmentation Analysis:

The Global Pulmonary Fibrosis Biomarkers Market is segmented on the basis of Type of Biomarkers, Application, End-user, and Region.

The market is divided into three categories based on Type of Biomarkers: Diagnostic Biomarkers, Prognostic Biomarkers, Predictive Biomarkers. The Diagnostic Biomarkers segment is the most prominent and significant in the Pulmonary Fibrosis Biomarkers market. Early and accurate diagnosis of pulmonary fibrosis (PF) is crucial for improving patient outcomes, and diagnostic biomarkers play a vital role in this process. These biomarkers are essential in identifying the presence of PF at its early stages, when intervention can still slow disease progression. With diseases like idiopathic pulmonary fibrosis (IPF) being challenging to diagnose due to their similarities with other lung conditions, diagnostic biomarkers help differentiate PF from other diseases, leading to quicker and more accurate diagnoses. Biomarkers such as KL-6, SP-D, and CCL18 are increasingly being used in clinical settings to aid in diagnosing IPF and other forms of pulmonary fibrosis. The growing awareness of PF and its high incidence rate in regions like the U.S. further intensifies the need for reliable diagnostic tools. This demand is driving the research and development of new, more efficient biomarkers, ensuring that the diagnostic biomarkers segment remains dominant in the market.

The market is divided into three categories based on application: Diagnosis, Treatment Monitoring, Drug Development. The diagnosis segment is the most significant in the Pulmonary Fibrosis Biomarkers market. Early and accurate diagnosis of pulmonary fibrosis (PF) is crucial for improving patient outcomes and enabling timely treatments. Since PF, particularly idiopathic pulmonary fibrosis (IPF), shares symptoms with other lung diseases, it is often misdiagnosed, making diagnostic biomarkers vital for distinguishing it from similar conditions. Biomarkers such as KL-6, SP-D, and CCL18 are commonly used in clinical practice for their ability to detect PF at early stages, when interventions are most effective in slowing disease progression. With the rising prevalence of PF, there is an increasing demand for precise diagnostic tools, driving the focus on developing new biomarkers for early detection. Moreover, as research institutions and healthcare providers emphasize early diagnosis, the diagnostic application remains central to the growth and innovation in the pulmonary fibrosis biomarkers market.

Pulmonary Fibrosis Biomarkers Market- Geographical Insights

North America is a leading region in the Pulmonary Fibrosis Biomarkers market due to its advanced healthcare infrastructure, high prevalence of pulmonary diseases, and ongoing research initiatives. The United States, in particular, has a significant share in the market, supported by the presence of top-tier research institutions, pharmaceutical companies, and a growing number of clinical trials. With approximately 200,000 individuals diagnosed with idiopathic pulmonary fibrosis (IPF) in the U.S., there is a strong demand for diagnostic biomarkers to aid early detection and management. Furthermore, government programs, like the National Institutes of Health (NIH), are funding research to identify and validate biomarkers, boosting innovation. The region's strong healthcare reimbursement systems also ensure that emerging biomarkers are adopted into clinical practice. Additionally, rising awareness about the disease and advancements in personalized medicine are further propelling market growth.

The United States plays a dominant role in the Pulmonary Fibrosis Biomarkers market due to its advanced healthcare system and substantial investment in medical research. With over 200,000 individuals diagnosed with idiopathic pulmonary fibrosis (IPF), the demand for effective biomarkers for early detection, prognosis, and treatment monitoring is growing rapidly.

The U.S. government, through agencies like the National Institutes of Health (NIH), is heavily funding research to discover new biomarkers. This, in turn, accelerates the development of diagnostic tools and therapies for IPF. The country also boasts a robust pharmaceutical industry that actively collaborates with research institutions to advance biomarker-driven solutions

Pulmonary Fibrosis Biomarkers Market- Competitive Landscape:

The competitive landscape of the Pulmonary Fibrosis Biomarkers market is marked by the presence of both established pharmaceutical giants and specialized biotech companies. Major players like Genentech, F. Hoffmann-La Roche, and Gilead Sciences dominate the market due to their extensive research capabilities and robust portfolios in pulmonary diseases.

These companies focus on advancing biomarker discovery, conducting clinical trials, and integrating biomarkers into treatment protocols. At the same time, smaller biotech firms like Biodesix and Thermo Fisher Scientific are making significant strides with innovative biomarker platforms and diagnostic tools tailored for pulmonary fibrosis. The competitive environment is also driven by strategic collaborations between pharmaceutical companies and research institutions, aimed at accelerating biomarker validation and commercialization. As the market evolves, companies are increasingly adopting personalized medicine approaches, further intensifying competition.

Recent Developments:

In October 2023, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for BMS-986278, a first-in-class oral lysophosphatidic acid receptor 1 (LPA1) antagonist, for the treatment of progressive pulmonary fibrosis (PPF), a severe and life-threatening disease. This designation expanded the company's product portfolio.

In March 2020, Bristol Myers Squibb entered into a collaboration with the Pulmonary Fibrosis Foundation (PFF) to identify biomarkers. The partnership aimed to accelerate the development of targeted therapies for this challenging condition, reflecting the company's commitment to enhancing patient outcomes. This initiative helped boost sales and revenue.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Biodesix, Inc.
  • Genentech, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories
  • PerkinElmer, Inc.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Novartis International AG
  • Johnson & Johnson
  • Mylan N.V.
  • Sanofi S.A.
  • Amgen Inc.

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET, BY TYPE OF BIOMARKERS- MARKET ANALYSIS, 2019 - 2032

  • Diagnostic Biomarkers
  • Prognostic Biomarkers
  • Predictive Biomarkers

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Diagnosis
  • Treatment Monitoring
  • Drug Development

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research & Academic Institutions

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Pulmonary Fibrosis Biomarkers Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Pulmonary Fibrosis Biomarkers Market Snippet by Type of Biomarkers
    • 2.1.2. Pulmonary Fibrosis Biomarkers Market Snippet by Application
    • 2.1.3. Pulmonary Fibrosis Biomarkers Market Snippet by End-user
    • 2.1.4. Pulmonary Fibrosis Biomarkers Market Snippet by Country
    • 2.1.5. Pulmonary Fibrosis Biomarkers Market Snippet by Region
  • 2.2. Competitive Insights

3. Pulmonary Fibrosis Biomarkers Key Market Trends

  • 3.1. Pulmonary Fibrosis Biomarkers Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Pulmonary Fibrosis Biomarkers Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Pulmonary Fibrosis Biomarkers Market Opportunities
  • 3.4. Pulmonary Fibrosis Biomarkers Market Future Trends

4. Pulmonary Fibrosis Biomarkers Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Pulmonary Fibrosis Biomarkers Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Pulmonary Fibrosis Biomarkers Market Landscape

  • 6.1. Pulmonary Fibrosis Biomarkers Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Pulmonary Fibrosis Biomarkers Market - By Type of Biomarkers

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type of Biomarkers, 2024 & 2032 (%)
    • 7.1.2. Diagnostic Biomarkers
    • 7.1.3. Prognostic Biomarkers
    • 7.1.4. Predictive Biomarkers

8. Pulmonary Fibrosis Biomarkers Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 8.1.2. Diagnosis
    • 8.1.3. Treatment Monitoring
    • 8.1.4. Drug Development

9. Pulmonary Fibrosis Biomarkers Market - By End-user

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-user, 2024 & 2032 (%)
    • 9.1.2. Hospitals & Clinics
    • 9.1.3. Diagnostic Laboratories
    • 9.1.4. Research & Academic Institutions

10. Pulmonary Fibrosis Biomarkers Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Pulmonary Fibrosis Biomarkers Industry

  • 11.1. Competitive Dashboard
    • 11.1.1. Competitive Benchmarking
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. Biodesix, Inc.
    • 11.2.2. Genentech, Inc.
    • 11.2.3. F. Hoffmann-La Roche Ltd.
    • 11.2.4. Bristol-Myers Squibb Company
    • 11.2.5. AbbVie Inc.
    • 11.2.6. Thermo Fisher Scientific Inc.
    • 11.2.7. Abbott Laboratories
    • 11.2.8. PerkinElmer, Inc.
    • 11.2.9. Eli Lilly and Company
    • 11.2.10. Gilead Sciences, Inc.
    • 11.2.11. Novartis International AG
    • 11.2.12. Johnson & Johnson
    • 11.2.13. Mylan N.V.
    • 11.2.14. Sanofi S.A.
    • 11.2.15. Amgen Inc.

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us